NR4A2 and neoplasm: Indeed, studies performed by Chen et al. have demonstrated that triple knockout of NR4A1, NR4A2, and NR4A3 (Nr4a TKO) in CD19-targeted CAR T cells enhances tumor regression in and survival of tumor-bearing mice [115].